SCHEMBL703677

SCHEMBL703677

COc1cccc(-c2nnn[nH]2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCUN1D1 Q96GG9 1/20 0.54
NR1H2 P55055 1/20 0.50
NR1H3 Q13133 1/20 0.50
XDH P47989 1/20 0.50
DYRK1A Q13627 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
AURKA O14965 1/20 0.47
NOTUM Q6P988 2/20 0.47
NR1I2 O75469 1/20 0.46
CYP1A2 P05177 1/20 0.46
VDR P11473 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2B6 P20813 1/20 0.46
AHR P35869 1/20 0.46
NR1I3 Q14994 1/20 0.46
PIN1 Q13526 1/20 0.46
NISCH Q9Y2I1 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8260189 0.84 TTK (0.51) DCUN1D1NR1H2NR1H3XDHDYRK1A
SCHEMBL6957090 0.83 FGFR2 (0.50) NOTUMKDM4EKMT2AGAALMNA
SCHEMBL12896130 0.83 GABRA1 (0.48) DCUN1D1ADORA2AMAPT
SCHEMBL706418 0.82 DHODH (0.45) DCUN1D1NR1H2NR1H3GAATSHR
SCHEMBL731571 0.82 NR1H2 (0.44) DCUN1D1NR1H2NR1H3XDHDYRK1A
SCHEMBL12761250 0.82 GP6 (0.37) DCUN1D1KDM4EKMT2AGAALMNA
SCHEMBL3601027 0.81 HDAC6 (0.41) DCUN1D1NR1H2NR1H3XDHDYRK1A
SCHEMBL6961795 0.80 KDM4E (0.51) NOTUMCYP1A2CYP2C9KDM4EKMT2A
SCHEMBL29227277 0.80 ACHE (0.48) ADORA2APIN1KMT2AGAALMNA
SCHEMBL30554756 0.80 ACHE (0.48) ADORA2APIN1KMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 CN claimed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US claimed
EP-2726515-B1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NAT RECH SCIENT (FR) 2015-04-01 EP claimed
US-20140206825-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-07-24 US claimed
EP-2726515-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES Centre National De La Recherche Scientifique (FR) 2014-05-07 EP claimed
WO-2013001235-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-01-03 WO claimed
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 CN disclosed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US disclosed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US disclosed
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
EP-2726515-B1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NAT RECH SCIENT (FR) 2015-04-01 EP disclosed
EP-2726515-B1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NAT RECH SCIENT (FR) 2015-04-01 EP disclosed
US-8927551-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
EP-0711762-A1 PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-05-15 EP disclosed
EP-0314104-B1 SILVER HALIDE PHOTOGRAPHIC MATERIALS FUJI PHOTO FILM CO., LTD. (JP) 1993-09-15 EP disclosed
US-5166046-A Light sensitive element with sensitizers KONICA CORPORATION (JP) 1992-11-24 US disclosed
US-5093222-A Contrast, negatives FUJI PHOTO FILM CO., LTD. (JP) 1992-03-03 US disclosed
EP-0439356-A1 Spectrally sensitized silver halide photographic material KONICA CORPORATION (JP) 1991-07-31 EP disclosed
EP-0314104-A2 Silver halide photographic materials FUJI PHOTO FILM CO., LTD. (JP) 1989-05-03 EP disclosed
US-4740455-A Heat developable light-sensitive material containing polymethine FUJI PHOTO FILM CO., LTD. (JP) 1988-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206825-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES ALK, TST, TEKT1 DCUN1D1 991/4885NR1H2 3954/4885NR1H3 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.